ADAG — Adagene Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1818838 ·
Last close
$1.48
Market Cap
$99.37M
52W High
$4.85
52W Low
$1.27
ADV30
371,244
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 133,575,568 127,909,840 44,122,150
Dec 2025 — — — — 78,263,297 74,523,782 42,913,750
Jun 2025 — — — — 66,516,743 62,828,156 28,604,954

Balance + Analyst (yfinance extras)

Retained Earnings
$-345,163,832
Inventory
—
Receivables
$153,025
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$9,290,815
EBITDA
$-21,952,354
Free Cash Flow
$-12,158,853
Enterprise Value
$123,018,568
Total Cash
$127,909,840
Total Debt
$6,091,037
Shares Out
67,143,344
Trailing EPS
$-0.38
Book Value
$1.33
ROE
-28.5%
ROA
-14.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,670,902 -21,438,295 -17,609,413 78,263,297 42,913,750 35,349,547 -15,657,450
Dec 2024 103,204 -35,951,543 -33,424,111 89,268,425 38,744,581 50,523,844 -29,700,985
Dec 2023 18,111,491 -23,719,866 -18,946,370 115,728,838 45,169,341 70,559,497 -28,454,839
Dec 2022 9,292,724 -83,920,683 -79,971,847 152,399,845 69,309,495 83,090,350 -48,611,687

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.56

Peers — same industry

TickerNameMarket CapLastDaily %
EQ Equillium, Inc. $99.61M $1.21 —
HSTC HST Global, Inc. $99.00M $0.70 —
IMUX IMMUNIC, INC. $100.01M $7.33 —
UNCY Unicycive Therapeutics, Inc. $101.35M $3.70 —
OGI ORGANIGRAM GLOBAL INC. $101.90M $0.71 —

News headlines (Yahoo Finance, 1h cache)

Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
2026-11-17 13:00 · Yahoo
City of Hope and Adagene Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
2026-11-17 13:00 · Yahoo
Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
2026-11-09 12:00 · Yahoo
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
2026-10-28 11:00 · Yahoo
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
2026-10-27 11:00 · Yahoo
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
2026-10-25 10:02 · Yahoo
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
2026-10-16 18:02 · Yahoo
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
2026-10-14 12:00 · Yahoo
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
2026-09-22 12:00 · Yahoo
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
2026-09-10 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.